AVROBIO Investor Relations Material
Latest events
M&A Announcement
AVROBIO
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AVROBIO Inc
Access all reports
AVROBIO, Inc. is a clinical-stage biotechnology company specializing in the development of gene therapies using a lentiviral-based platform. These therapies are designed to treat rare diseases with a single dose, and involve modifying hematopoietic stem cells extracted from patients. AVROBIO focuses on a range of genetic disorders, employing its proprietary plato® platform to optimize these therapies. Notable diseases targeted by AVROBIO's gene therapies include Gaucher disease, Pompe disease, cystinosis, and Hunter syndrome, with several treatments in various stages of clinical trials. The company was established in 2015 and is based in Cambridge, Massachusetts. Its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
AVRO
Country
🇺🇸 United States